JAK2 and myeloproliferative neoplasm: The NAP rate of the MPN patients with JAK2 mutations was high compared with patients with CALR mutations (n = 10; median 87.5 %; range 74–100 %) and may be explained by the increase in strongly NAP-positive neutrophils (score 4 or 5).